Chengchen Wang, MD

Department of Radiation Oncology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Cancer Hospital

Chongqing, jiangbei

Disclosures:

Employment: none
Compensation: none
Ownership: none
Leadership: none

Presentations

Sep 29

3652 - Phase II Trial of Tislelizumab plus Chemotherapy with Response-Adapted Radiotherapy for De Novo Metastatic Nasopharyngeal Carcinoma

Poster Hall - Exhibit Hall A

03:45pm - 05:00pm ET